Maintenance chemotherapy in the management of epithelial ovarian cancer

被引：0
作者：
Maurie Markman
机构：
[1] Cancer Treatment Centers of America,College of Medicine
[2] Drexel University,undefined
来源：
Cancer and Metastasis Reviews | 2015年 / 34卷
关键词：
Epithelial ovarian cancer; Chemotherapy; Maintenance therapy; Paclitaxel; Anti-angiogtenic agents;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The fundamental goal of maintenance therapy of cancer is to extend a clinically meaningful survival endpoint (overall, symptom-free, progression-free) while at the same time not substantially interfering with a patient’s quality of life. Several phase 3 randomized trials in ovarian cancer involving different anti-neoplastics (e.g., paclitaxel, anti-angiogenic agents, olaparib) have revealed an improvement in progression-free survival with generally acceptable side effect profiles, and as a result represent in appropriately selected patients a rational therapeutic strategy.
引用
收藏
页码：11 / 17
页数：6
相关论文
共 117 条
[1]  
Maughan TS(2003)Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomized trial Lancet 361 457-464
[2]  
James RD(2010)Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus Clinical Cancer Research 11 521-529
[3]  
Kerr DJ(1991)Interrupted versus continuous chemotherapy in patients with metastatic breast cancer New England Journal of Medicine 325 1342-1348
[4]  
Owonikoko TK(1981)Epithelial carcinoma of the ovary: current strategies Annals of Internal Medicine 95 98-111
[5]  
Ramalingam SS(1978)Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy New England Journal of Medicine 299 1261-1266
[6]  
Belani CP(1982)Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized trials New England Journal of Medicine 307 1416-1421
[7]  
Muss HB(1996)Second malignant neoplasms among long-term survivors of ovarian cancer Cancer Research 56 1564-1570
[8]  
Case LD(1997)A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study Annals of Oncology 8 327-333
[9]  
Richards F(1993)A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA) Gynecologic Oncology 49 30-36
[10]  
Katz ME(1992)Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma Gynecologic Oncology 45 284-289
12345678910